Conflicting industry views over need for devices head at UK's MHRA (Medicines and healthcare Products Regulatory Agency)
This article was originally published in Clinica
Executive Summary
Following Dr Ian Gibson's raising the issue of why there was no longer a head of the devices and diagnostics section at the Medicines and healthcare Products Regulatory Agency, Amanda Maxwell spoke to the Association of British Healthcare Industries (ABHI), the British In Vitro Diagnostics Association and the British Healthcare Trades Association to see how they are coping with the lack of authority figure for devices and found two surprisingly different views
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.